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Involvement of imidazoline receptors (IR) in the regulation of vasomotor tone as well as in
the mechanism of action of some centrally acting antihypertensives has received tremen-
dous attention. To date, pharmacological studies have allowed the characterization of three
main imidazoline receptor classes, the I1-imidazoline receptor which is involved in central
inhibition of sympathetic tone to lower blood pressure, the I2-imidazoline receptor which
is an allosteric binding site of monoamine oxidase B (MAO-B), and the I3-imidazoline re-
ceptor which regulates insulin secretion from pancreatic β-cells. All three imidazoline re-
ceptors represent important targets for cardiovascular research. The hypotensive effect of
clonidine-like centrally acting antihypertensives was attributed both to α2-adrenergic re-
ceptors and nonadrenergic I1-imidazoline receptors, whereas their sedative action involves
activation of only α2-adrenergic receptors located in the locus coeruleus. Since more selec-
tive I1-imidazoline receptors ligands reduced incidence of typical side effects of other cen-
trally acting antihypertensives, there is significant interest in developing new agents with
higher selectivity and affinity for I1-imidazoline receptors. The selective imidazoline recep-
tors agents are also more effective in regulation of body fat, neuroprotection, inflammation,
cell proliferation, epilepsy, depression, stress, cell adhesion, and pain. New agonists and
antagonists with high selectivity for imidazoline receptor subtypes have been recently de-
veloped. In the present review we provide a brief update to the field of imidazoline research,
highlighting some of the chemical diversity and progress made in the theoretical studies of
imidazoline receptor ligands.
Introduction
Two decades ago Bousquet et al. [1] discovered that the clonidine-
like centrally acting antihypertensives produced their pharmaco-
logical effect by interaction not only with the α2-adrenenoceptors
(α2-AR) but also with imidazoline receptors (imidazoline binding
sites [IBSs]). The IBSs were pharmacologically distinct from the
α2-AR because they were not activated by catecholamines [1].
They found a positive correlation between the hypotensive po-
tency of imidazoline compounds and their affinity for imidazoline
receptors but not for α2-adrenoceptors [2,3].
In the present study, we seek to distinguish the ligand selectiv-
ity profile of I1-IBS relative to other binding sites for imidazolines,
demonstrate the specific activation of transmembrane signaling
pathways by I1-imidazoline receptors and review the diverse and
complex function of I1-imidazoline receptors ligands.
Specific imidazoline receptors, I1-imidazoline receptors (I1-IR),
I2-imidazoline receptors (I2-IR), and I3-imidazoline receptors
(I3-IR), have been characterized by extensive biochemical and
physiological studies [4,5] and highly selective novel imidazoline
agents have been developed without α2-AR activity [6].
Imidazoline I1-receptors in the rostral ventrolateral medulla
(RVLM) are important for the sympathoinhibitory action of
clonidine-, rilmenidine-, and moxonidine-like antihypertensive
drugs. The mechanism by which central antihypertensives low-
ers blood pressure is a result of activation of both α2-AR and
I1-IRs in the RVLM [3,7]. The α2-AR agonists directly inhibit
presympathetic RVLM neurons, while the I1-IR agonists increase
the release of catecholamines in the RVLM. The catecholamines
depress presympathetic RVLM neurons by activating α2-AR [3,7].
Compared with clonidine, newer centrally acting antihyperten-
sive drugs such as rilmenidine and moxonidine are more selec-
tive for I1-imidazoline receptors than for α2-adrenergic receptors.
Rilmenidine and moxonidine cause only few α2-adrenoceptor-
mediated side effects because they posses better selectivity for
I1-IRs.
In order to test the imidazoline hypothesis, the effects of cloni-
dine on blood pressure and heart rate in α2ABC-deficient mice
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were determined [8]. Clonidine, moxonidine, and rilmenidine
failed to significantly decrease mean arterial pressure in α2ABC-
deficient mice [8]. These findings have further confirmed that ac-
tivation of α2-AR is required for hypotensive effect of the central
antihypertensives.
The second-generation agents, such as rilmenidine and mox-
onidine, produce hypotension and sympathetic inhibition by an
action principally on I1-imidazoline receptors rather than α2-
adrenoceptors [3,7,9]. Many studies have investigated close inter-
dependence and interaction of these two receptors at the cellular
level.
Many efforts have been made to identify the proteins bearing
the different imidazoline-binding sites. The I1-IR protein struc-
tures have not yet been solved to date. Only imidazoline receptor
antisera-selected (IRAS-1) gene candidate for the I1-IR protein has
been cloned [10–12].
Nischarin, a homolog of human IRAS [10], plays an important
role in cell signaling and function [12]. New in vivo studies from
Abdel Rahman’s group presents evidence that nischarin is essen-
tial for the initiation of neuronal signaling triggered by I1 recep-
tor activation in the RVLM and subsequent hypotensive response
[11]. This evidence is supported by the findings that knockdown
of nischarin expression in the RVLM virtually abolishes the I1R
(rilmenidine)-mediated enhancement of phosphorylated extracel-
lular signal-regulated kinase (pERK)1/2 production in the RVLM
and the associated hypotension [11]. Transfection studies with
IRAS-1 cDNA, have revealed a modulatory role for imidazoline
receptors on coincidently activated receptors in the same cell, in-
cluding the α2A-adrenergic and fibronectin receptors [13].
Since the IBS may only be formed when IRAS-1 is complexed
to the fibronectin receptor or other partner proteins [13], charac-
terization of I1-ligand—IRAS-1 complexes require special experi-
mental procedure.
The I1-sites have been shown to be coupled to a G protein
in synaptic plasma membranes of the bovine brainstem [14,15],
in the human platelets [16], and in the rat pheochromocytoma
cells (PC12) [17,18]. I1 receptors are preferentially bound by
2-aminoimidazolines ([3H]-clonidine), while show medium affin-
ity for imidazolines ([3H]-idazoxan), and low affinity for guani-
dines (amiloride) [19–21].
The I2 receptors are allosteric binding site associated with the
catalytic site of monoamine oxidase (MAO), but also on other
non-MAO oxidative enzymes [22].
The I2-imidazoline-binding proteins were purified from rabbit
kidney [23], adrenal chromaffin cells [24], and RINm5F pancre-
atic cells [25]. The sequence of these proteins presented some ho-
mology with that of the MAO enzyme [23–25].
The I2 sites are located principally in the outer membrane of mi-
tochondria of peripheral and central tissues [26,27], such as cen-
tral nervous system (especially in glia cells [28]), blood platelets,
liver, adipocytes, and kidney.
I2 receptors are characterized by their high affinity for imidazo-
lines and guanidines, and lower affinity for 2-aminoimidazolines
[29]. Further pharmacological studies demonstrated existence of
two I2-receptor subtypes, I2A and I2B, depending on their affinity
for guanidine derivative-amiloride [26].
Some previous studies reported experimental data that pancre-
atic imidazoline receptors and sympathetic presynaptic imidazo-
line receptors did not fulfill the criteria for the definition of I1 or
I2 receptors. Such sites were initially called non-I1, non-I2 recep-
tors [30,31] and later were defined as I3 receptors [32,33]. The I3
receptors in pancreatic β-cells are involved in regulation of insulin
secretion in a manner, which is not typical of I1- or I2-receptor re-
lated phenomenon [30,32–35]. The imidazoline efaroxan is a se-
lective agonist at the I3 receptor and its imidazole analog (KU14R)
is an antagonist [33]. However, attempts to characterize the asso-
ciated IBSs have been unsuccessful because of the lack of specific
radioligands.
The reduced incidence of side effects of more selective imidazo-
line receptor ligands together with difficulties in separating effects
of an interaction with α2-AR from those of imidazoline receptors
[34], were driving force to search for new selective imidazoline
agents, to identify imidazoline receptors and their endogenous lig-
ands, and to examine functional effects of stimulation of particular
I1-, I2-, and I3-imidazoline receptors.
I1-imidazoline receptors ligands will be compared in function of
their chemical structure, binding affinity, and selectivity for the
I1-imidazoline receptors.
Imidazoline Endogenous Ligands
The majority of the currently used hypotensive compounds are
synthetic imidazoline derivatives. If the naturally occurring lig-
ands could be identified, they may have an improved selectiv-
ity profile and hence could be the starting point for the devel-
opment of a new range of antihypertensive agents. Therefore,
elucidation of the structure of the endogenous ligand(s), called
clonidine-displacing substances (CDS), for IBSs has been a major
goal for many years. The CDS was originally identified in extracts
of rat and bovine brain [36] but may also be present in periph-
eral tissues and in the circulation [37,38]. The CDS, such as agma-
tine, imidazole-4-acetic acid-ribotide, and β-carboline compounds
(Figure 1), can bind with high affinity to imidazoline sites and
to α2-adrenoceptors [39]. Agmatine possesses the common ami-
dine motif and can accordingly displace specific radioligand bind-
ing from α2-adrenoceptors and IBSs [39].
Initially, agmatine [40] and imidazole-4-acetic acid ribotide [41]
have been identified as endogenous ligands for the imidazoline
receptors.
The agmatine is a polyamine formed by decarboxylation of
L-arginine by arginine decarboxylase (ADC) in mammalian tissues
[40]. Agmatine binds with a moderate affinity α2-adrenoceptors as
well as to I1- and I2-binding sites [40]. This guanidine-aliphatic-
amine seems to be either an endogenous antagonist or inverse ag-
onist at imidazoline receptors, but also has major effects on NMDA
receptors and neuronal nitric oxide synthase [42,43]. This putative
neurotransmitter interacts with a variety of receptors and has been
implicated in mediation of stress responses, analgesia, drug addic-
tion and withdrawal, convulsions, and neuroprotection. [44]. Ac-
tivation of imidazoline I2A receptors by agmatine in adrenal gland
lowers plasma glucose in streptozotocin-induced diabetic rats (STZ
rats) [45].
The imidazole-4-acetic acid-ribotide (IAA-RP) is the endoge-
nous agonist for I1-IRs and I3-IRs in adrenal medulla and in pan-
creatic tissue [41].
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Figure 1 Chemical structures of endogenous
ligands: Agmatine, Imidazoleacetic acid-Ribotide,
Harmane, and Harmalan.
Also, β-carboline compounds, such as harmane [46,47] and
harmalan [48], have been proposed as putative endogenous sub-
strates of either I1- or I2-imidazoline receptors. These compounds
have been shown that act as endogenous ligands at certain imida-
zoline receptors and have central effects on blood pressure [47].
The potency of harmane on blood pressure is similar to that of the
clonidine [47].
The endogenous ligands were assessed for binding affinities at
I1-IR, I2-IR, and α2-adrenoceptors on rat brain and kidney mem-
branes [49,50] and binding affinities at I2-IR on human placenta
and rat liver membranes [39].
I1-Imidazoline Receptor Ligands
The I1 subtype of imidazoline receptors has been thoroughly char-
acterized by binding assays using radiolabeled clonidine analogs
and its pharmacological selectivity assessed [7,51,52]. The cou-
pling of I1-imidazoline receptors to G proteins has been sug-
gested by the sensitivity of the imidazoline-specific binding to
GTP or nonhydrolysable analogs in the canine prostate [53], in
the chromaffin cells [16,51], and in the bovine brainstem [54].
Effects of imidazolines on classical second messenger systems of
G protein-coupled receptors, either cAMP or inositol-phosphates
and diacylglycerol (DAG), have been studied in various mod-
els, including rat adrenal glands, bovine chromaffin cells, and
rat brain. Transduction pathways of the I1-imidazoline recep-
tors in the PC12 cells have been associated with activation of a
phosphatidylcholine-specific phospholipase C (PC-PLC) [17] and
inhibition of an adenylate cyclase [18].
Benazoline and other I1-imidazoline receptor ligands are able
to dose dependently decrease forskolin-stimulated cAMP content
in cells expressing only I1-imidazoline receptors (PC12 cells and
NG10815 cells) [18]. Interestingly, although benazoline and mox-
onidine were agonists for both PC-PLC and cAMP pathways, some
agonists for the cAMP pathway (efaroxan) had antagonist effects
on the PC-PLC pathway [17,55]. These findings have opened new
field of investigations aiming to determine the existence of a cross
talk between the different transduction pathways and to identify
their respective contributions to the physiological roles of the I1-
imidazoline receptors.
On the other hand, pharmacological studies have shown that
I1-imidazoline receptors are involved in several functions such as
regulation of the cardiovascular function [1,3], modulation of the
ocular pressure [56], renal sodium excretion [57], and control of
the catecholamine release from chromaffin cells [58].
The central hypotensive effect of the I1-imidazoline receptor lig-
ands with mixed (I1/α2) binding profiles has been in significant
correlation with their affinity for I1-IRs [2,3]. Imidazoline antag-
onists such as idazoxan competitively antagonized the centrally
induced hypotensive effect of the I1-IRs ligands, while yohimbine,
a α2-ARs antagonist, blocks the hypotensive effect of the ligands
but usually in a noncompetitive manner [59]. The hypotensive ef-
fects of more selective I1-imidazoline receptor ligands, such as ril-
menidine and moxonidine, was clearly prevented by idazoxan, an
imidazoline I1-IR antagonist, whereas it was very weakly antago-
nized by antagonist for the α2-adrenoceptors, such as yohimbine
[60,61]. Furthermore, recent studies have found that hypotensive
effect of the selective imidazoline agents was facilitated by the ac-
tivation of α2-adrenoceptors using α-methylnoradrenaline [62].
In more detail, the adrenergic cell provides excitatory signals to
the preganglionic sympathetic neurons (PGSN) in the intermedi-
olateral cell column of the spinal cord to alter sympathetic dis-
charges to the peripheral tissues. Its activity can be inhibited by
neurotransmitters that are released from the activation of I1-IRs
located on the noradrenergic (NA) cell terminals, or from the stim-
ulation of terminal α2A-adrenoceptors located on the interneuron
containing γ -aminobutyric acid (GABA). The serotonergic (5-HT)
innervation may enhance the excitatory signals from the adrener-
gic cell [59–62].
All these results can be summarized as follows:
 An action on medullary I1-imidazoline receptors alone is suffi-
cient to inhibit vasomotor tone and therefore to reduce blood
pressure.
 I1-imidazoline receptors are involved in the hypotensive effects
of I1-IR ligands.
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 The integrity of the α2-adrenoceptors included in the sympa-
thetic centers and pathways appears to be required for the de-
velopment of the hypotensive effects of at least α2-adrenergic
agonists.
 A cooperative interaction between imidazoline receptors and
α2-adrenoceptors seems to account for the marked and rapid
hypotensive effect caused by I1-IR ligands [59–62].
Many different families of I1-imidazoline receptors ligands,
such as guanidine derivatives, imidazoline compounds, endoge-
nous amines, and carbolines have been synthesized and examined
for I1-, I2-, α2A-, α2B-, α2C-binding affinities [7,15,18,38,49,51,
63–65].
Compilation of agmatine structure and imidazoline ring
leads to a new family of imidazoline/α2-adrenoceptor ligands,
4(5)-(2-aminoethyl)imidazoline derivatives. The guanidine moi-
ety included into heterocyclic ring improves the affinities of the
resultant fusion compounds in comparison to agmatine itself [64].
Previously used radioligands to characterize the I1-IR, such
as [3H] clonidine and [125I] p-iodoclonidine [51,52], were able
to bind with similar affinities to α2-ARs and to I1-IR [66].
Therefore adequate characterization of the I1-IR subtype was very
difficult. Recently, new imidazoline analogs, such as cis-/trans-
dicyclopropylmethyl-(4,5-dimethyl-4,5-dihydro-3H-pyrrol-2-yl)-
amine (LNP-509) [67], 2-(2-chloro-4-iodo-phenylamino)-5-
methyl-pyrroline (LNP 911) [63], (2-(5-azido-2-chloro-4-iodo-
phenylamino)-5-methyl-pyrroline (LNP 906) [68], (+)-5-(2-
bromophenoxy)-methyl-2-amino-4,5-dihydro-1,3-oxazole
(S23515) [69], (+)-2-(2-fluoro-5-methylphenyl)-4,5-dihydro-
1H-imidazole (S23757) [69], with high affinity and selectivity
for the I1-IRs were synthesized. The LNP 509 and S23515 cause
hypotension when injected alone into the brainstem [67,69].
The LNP 906 and S23757 clearly antagonized the decrease
in forskolin-stimulated cAMP level induced by I1-IR agonists
[68,69]. Finally, LNP 911 is not able to dose dependently decrease
forskolin-stimulated cAMP content in cells expressing only
I1-imidazoline receptors, but it behaves as an allosteric enhancer
[63]. The LNP 911 was radioiodinated and its binding properties
characterized in different membrane preparations. While the
hypotensive actions of these highly selective agents, such as LNP
509 [67], S23515 [69], and S23757 [69], have been documented
[67,69] no full description of their cardiovascular actions has
appeared to date in the literature.
Because of diverse I1-IRs binding affinities of the ligands ob-
tained with different radioligands (such as [125I] p-iodoclonidine
([125I] PIC) and [125I] LNP 911) and different membrane prepa-
rations (such as PC12 and human platelets, Table 1) [15,18,63],
it is not possible to compare the ligands binding affinities data of
various competition binding studies.
The correlation between the pKi of the high affinity I1-IR
ligands (clonidine; lofexidine; BDF 6143; rilmenidine; p-
iodoclonidine; LNP 911) on [125I] LNP 911 binding sites and the
pKi of the same drugs on [125I] PIC binding sites [63], together
with the fact that PIC and LNP 911 were able to displace the same
amount of [125I] LNP 911 total binding [63] indicate that identical
I1-binding sites are concerned.
Because moxonidine, efaroxan, and benazoline were described
as high-affinity I1-IRs ligands in different models [17,18] but dis-
placed [125I] LNP 911 with rather low affinity, relationships be-
tween the ligands and [125I] LNP 911 were studied in details [63].
These analyses have found out that I1-IRs are submitted to a com-
plex allosteric modulation by the use of LNP 911. Actually, the
LNP 911 behaves as an allosteric enhancer and potentates the ef-
fects obtained with I1-IR agonists [63].
The lack of a clearly identified molecular structure for the I1-IR
[10–12] and modulatory role for imidazoline receptors on coin-
cidently activated α2A-adrenergic and fibronectin receptors in the
same cell [13] are making virtual docking study very difficult. Fur-
thermore, importance of I1-IR selective ligands being available for
structural, functional, and pharmacological investigations on I1-
IRs, are the factors that have encouraged scientists to undertake
a modeling study addressing the development of pharmacophore
and quantitative structure activity relationship (QSAR) models
[70–80]. The modeling studies have indicated on the physico-
chemical interactions modulating I1-IR affinity and on the key
molecular determinants of I1-IR/α2-AR and I1/I2-IR selectivity.
The results from the modeling studies can be used for the ratio-
nal design of new, more selective, and high affinity I1-IR ligands.
The developed QSAR models for I1-IR ligands (Figure 2) have
indicated that an increase in lipophilicity (logDpH7.4), molar re-
fractivity, and dipole moment value, together with a decrease in
N-charge in the heterocyclic moiety influence on better affinity for
I1 receptors [70,71]. Furthermore, highest occupied molecular or-
bital energy and lipophilicity (ClogP) of the ligands are important
parameters for evaluation of I1/α2-selectivity [70].
The other 2D-QSAR studies [76–80] have selected the elec-
trostatic and steric properties as the most relevant ones in ex-
plaining the modulation of both I1 and I2 affinity. In agree-
ment with the 2D-QSAR study, the combination of the steric
and electrostatic field (for affinity at I1-IR) and the steric field
in combination with the lipophilic one (for affinity at I2-IR),
were the most important molecular interaction fields (MIFs) pa-
rameters, identified by the 3D-QSAR CoMFA, GRID, and GOLPE
approaches [80].
The pharmacophore hypotheses, developed for I1-IR ligands, in-
dicated for the following five features: a hydrogen-bond donor
group (HBD), two hydrophobic (HY1 and HY2) regions, an aro-
matic ring (AR), and a positive charge (PC) [80]. The pharma-
cophore for the I2-IR ligands was made up of only four features:
two hydrophobic (HY1 and HY2) regions, an AR, and a PC [80].
2D- and 3D-quantitative SAR study, performed on a series of im-
idazoline congeners, highlighted that good lipophilicity, extended
also to the ortho position of the phenyl ring, was favorable but not
decisive for significant I2-IBS affinity [78,81]. Furthermore, the
unsubstituted ethylenic bridge, between the aromatic portion and
imidazoline nucleus of the 2-phenoxymethylimidazoline analogs,
is proved to be determinant in inducing high I2-IR selectivity with
regard to I1-IR and α2-ARs [65,81].
Pharmacological Effects of I1-Imidazoline Agents
Hypertension is often observed as part of a more complex combi-
nation of diseases, such as obesity, hyperlipidemia, and hyperin-
sulinemia [82].
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Table 1 Inhibitory binding constants (Ki) for ligands in competition binding studies with [125I] LNP 911 on PC12 cells [64], [125I] PIC on PC12 cells [18,64], and
[125I] PIC at human platelet I1-IR [15]
Ki (I1-IR) [nM] with [125I]LNP 911 Ki (I1-IR) [nM] with [125I]PIC Ki(I1-IR) [nM] with [125I]PIC at
Compound on PC12 cells [64] on PC12 cells [18,64] human platelet I1-IR [15]
LNP 911 1.4 ± 1.7 0.3 [64]
p-Iodoclonidine (PIC) 9.5 ± 6.3 0.8 [64] 4.8 ± 1.2
Rilmenidine 43.9 ± 0.5 20.0 [64] 59.2 ± 5.8
BDF 6143 62.3 ± 7.0 28 ± 6.0 [18] 232.0 ± 126.0
Lofexidine 507 ± 69 5.6 [64]
Clonidine 693 ± 37 125 ± 75 [18] 55.0 ± 10.0
Benazoline 3,903 ± 437 1.3 [18]
p-Aminoclonidine 4,492 ± 784
Moxonidine 7,215 ± 461 34 ± 5 [18] 4.2 ± 3.2
Idazoxan 7,655 ± 876 1,255.0 ± 745.0
Efaroxan 8,567 ± 747 144 ± 170 [18] 52.4 ± 30.4
Figure 2 Chemical structures of I1-IR ligands.
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Rilmenidine and moxonidine induce fall in plasma cate-
cholamines, rennin, and antidiuretic hormone [83–87], while
clonidine, rilmenidine, and moxonidine effectively regress left
ventricular hypertrophy [88–90] and reduce atrial natriuretic pep-
tide levels [91]. Therefore, the drugs of the second generation
were shown to increase renal blood flow, potassium excretion,
natriuresis associated with inhibition of sodium reabsorption,
and diuresis, whereas the sympathetic renal nerve activity was
markedly decreased [92].
The α2-adrenoceptors in the pancreas reduced insulin secretion
and increase glucagon release, while I1-IR activation had the op-
posite effect. Thus selective I1-IR agonists are capable of increas-
ing the glucose-induced insulin secretion from pancreatic β-cells
[93–96]. Furthermore, moxonidine improves the metabolic profile
in patients with hypertension and diabetes mellitus or impaired
glucose tolerance [97].
Conclusion
The low incidence of the side effects, antiarrhythmic effects, and
beneficial metabolic and renal effects of second-generation I1-IR
ligands suggest that they may provide a very useful therapy, which
may be further enhanced by the development of more selective I1-
IR agents.
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